FDA Approved Indications for this Orphan Drug:For chronic replacement therapy of individuals having congenital deficiency of alpha1- proteinase inhibitor with clinically demonstrable panacinar emphysema.
FDA Marketing Approval issued as of:
Orphan Drug exclusivity ends on:
Company Making and Marketing this drug:
FDA Designation Date:
FDA Drug Designation:
For replacement therapy in the alpha-1-proteinase inhibitor congenital deficiency state.